New York, NY -- (ReleaseWire) -- 03/19/2013 --Galena Biopharma, Inc. (NASDAQ:GALE) announced it has entered into an agreement with Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, to acquire Abstral(R) (fentanyl) Sublingual Tablets for sale and distribution in the United States.

Abstral is an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) in patients who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain.

Abstral was approved by the U.S. Food and Drug Administration (FDA) in January 2011.

Under the terms of the agreement, Galena Biopharma will pay Orexo $10 million upfront and $5 million within the first twelve months of closing, plus low double digit royalties and one-time milestone payments based on pre-specified net sales.

Find out more on GALE here:

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) announced last week that U.S. Food and Drug Administration (FDA) approval of Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a novel product indicated for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek is a receptor targeted radiopharmaceutical designed to identify these lymph nodes which have the highest probability of harboring cancer and thereby assist physicians in the staging of such patients.

The approval of Lymphoseek is based on data from more than 540 subjects receiving Lymphoseek. Lymphoseek will be sold and distributed in the U.S. on an exclusive basis by Cardinal Health, Inc.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of precision diagnostics and radiopharmaceutical agents.

Get the latest trend analysis reports on NAVB here:

About WallStreetScoop.net
WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: http://www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop

Media Relations Contact

Thomas Greene

View this press release online at: http://rwire.com/224919